ARKANSAS REGISTER



Transmittal Sheet

Use only for **FINAL** and **EMERGENCY RULES**

Secretary of State

John Thurston

500 Woodlane, Suite 026 Little Rock, Arkansas 72201-1094 (501) 682-5070



www.sos.arkansas.gov

For Office Use Only:		
Effective Date	Code Number	
Name of Agency Arkansas Department		
Department Division for Health Protect	ion, Pharmacy Services Section	
Contact_Laura Shue	_E-mail_Laura.Shue@arkansas.gov_Phone_5	01-661-2297
Statutory Authority for Promulgating Rule	es Ark. Code Ann. § 5-64-216; Ark. Code Ann. § 5-64-10	1, et seq. (Supp. 2023)
Rule Title: List of Controlled S	Substances	
Intended Effective Date (Check One)	Legal Notice Published	Date 12/30/2023
Emergency (ACA 25-15-204)		01/29/2024
10 Days After Filing (ACA 25-15-204)	Final Date for Public Comment	
Other (Must be more than 10 days after filing date.)	Reviewed by Legislative Council	03/15/2024
(Must be more than 10 days after ming dates)	Adopted by State Agency	10/26/2023
Electronic Copy of Rule e-mailed from: (Require	d under ACA 25-15-218)	
Laura Shue Laura.Sh	luc@arkarioas.gov)3/25/2024
I Hereby Certi	ON OF AUTHORIZED OFFICER fy That The Attached Rules Were Adopted	Date
In Compliance with the Ar	ckansas Administrative Act. (ACA 25-15-201 et. seq.)	
501-661-2297	Laura.Shue@arkansas.gov	
Phone Number	E-mail Address	
General Counsel	Title	
03/25/2024	A	
Marie Control of the	Date	

List Of Controlled Substances



For the State Of Arkansas Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Secretary of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Secretary of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Secretary of the Arkansas Department of Health. A "*" denotes the substance was scheduled prior to April, 1979.

I, Shane David, Pharm.D., Section Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., Branch Chief
Pharmacy Services Section

fiddleton

STATE OF ARKANSAS)
)
COUNTY OF SALINE)

I, Marci Middleton-Yates, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this 18th day of March, 2024.

Notary Public

My commission expires

MARCI MIDDLETON
MY COMMISSION # 12403833
EXPIRES: April 25, 2025
Saline County

ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Code Annotated §5-64-201 and §5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the 26th day of October, 2023, and after a Public Hearing on the 23rd day of January, 2024, held in Little Rock, Arkansas, at the State Department of Health Building.

Jennifer Dillaha, MD

Secretary of Arkansas State Board of Health Director of the Arkansas Department of Health

ARTICLE II

SCHEDULE I

- (a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) <u>Opiates: (Narcotic Drugs)</u> Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

(1) A	cetylmethadol	9601*
(2) A	llylprodine	9602*
(3) A	lphacetylmethadol (except Levo-alphacetylmethadol (LAAM)	-9603*
(4) A	lphameprodine	9604*
(5) A	lphamethadol	9605*
(6) B	enzethidine	9606*
(7) B	etacetylmethadol	9607*
(8) B	etameprodine	9608*
(9) B	etamethadol	9609*
(10)	Betaprodine	9611*
(11)	Dextromoramide	9613*
(12)	Diampromide	9615*
(13)	Diethylthiambutene	9616*
(14)	Difenoxin	9168*
(15)	Dimenoxadol	9617*
(16)	Dimepheptanol	9618*
(17)	Dimethylthiambutene	9619*
(18)	Dioxaphetyl butyrate	9621*
(19)	Dipipanone	9622*
(20)	Ethylmethylthiambutene	9623*
(21)	Etoxeridine	9625*
(22)	Furethidine	9626*
(23)	Hydroxypethidine	9627*

(24)	Ketobemidone	9628*
(25)	Levomoramide	9629*
(26)	Levophenacylmorphan	9631*
(27)	Morpheridine	9632*
(28)	MPPP [other name(s): (1-methyl-4-phenyl-4-propionoxypiperidine)]	9661-(10-1985)
(29)	Noracymethadol	9633*
(30)	Norlevorphanol	9634*
(31)	Normethadone	9635*
(32)	Norpipanone	9636*
(33)	PEPAP [other name(s): 1-(2-phenylethyl)-4-phenyl-4 acetyloxypiper-idine] - 9	9663-(10-1985)
(34)	Phenadoxone	9637*
(35)	Phenampromide	9638*
(36)	Phenomorphan	9647*
(37)	Phenoperidine	9641*
(38)	Piritramide	9642*
(39)	Proheptazine	9643*
(40)	Properidine	9644*
(41)	Propiram	9649*
(42)	Racemoramide	9645*
(43)	Tilidine	9750-(9-1981)
(44)	Trimeperidine	9646*
(45)	Acetyl norfentanyl [other name(s): N-phenyl-N-4-piperidinyl-acetamide]	(4-2017)
(46) d	AH-7921 [other name(s): 3,4-dichloro- <i>N</i> - <u>[(1</u> -dimethylamino)cyclohexylmethyl]benzamide]	-9551-(4-2017)
	W-18 [other name(s): 1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide]	(4-2017)
	W-15 [other name(s): 1-phenylethylpiperidylidene-2-(4-chlorophenyl)Sulfonamide]	(4-2017)
(49)	MT-45 [other name(s): 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine]	9560-(4-2017)
(50) N	U-47700 [other name(s): trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide]	9547-(4-2017)
	Fentanyl-related substances, their isomers, esters, ethers, salts and salts of somers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section	ı

	of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is turally related to fentanyl by one or more of the following modifications:	(4-2021)
(i)	Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;	
(ii)	Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;	
(iii)	Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;	
(iv)	Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or	
(v)	Replacement of the N-propionyl group by another acyl group.	
(vi)	Fentanyl-related substances shall include, but are not limited to:	
(.	A) Acetyl-alpha-methylfentanyl [other name(s): (N-[1-[1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide)]	9815-(2-1986)
(B) Alpha-methylfentanyl [other name(s): (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propronanilide; 1-(1-methyl-2-phenylethyl)-4(N-propanilido)piperidine)]	- 9814-(6-1982)
(C) Alpha-methylthiofentanyl(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	- 9832-(2-1986)
(D) Beta-hydroxyfentanyl [other name(s): (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)]	- 9830-(2-1986)
(E) Beta-hydroxy-3-methylfentanyl [other name(s): N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropamamide]	- 9831-(2-1986)
(F) 3-Methylfentanyl [other name(s): (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-Phenylpropanamide)]	9813-(10-1985)
(G) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	- 9833-(2-1986)
(H) Para-fluorofentanyl [other name(s): (N-[4-fluorophenyl)-N-[1-(2-phenenthyl)-4-piperindinyl]propananmide]	9812-(11-1986)
(I) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamid	
(.	J) Acetyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide]	9821-(4-2017)
(K) Butyryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide]	9822-(4-2017)
(L) Beta-hydroxythiofentanyl [other name(s): N-{1-[2-hydroxy-2-(thiophen-2yl)ethyl]piperidin-4-yl}-N-phenylpropionamide]	

(M) Acetyl fentanyl 4-methylphenethyl analog [other name(s): N-{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl}-N-phenyl-acetamide]	(4-2017)
(N) Valeryl fentanyl [other name(s): N-phenyl-N[1-(2-phenylethyl)-4-piperidinyl]-pentanamide]	9840-(4-2017)
(O) Furanyl fentanyl [other name(s): N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide]	9834-(4-2017)
(P) Isobutyryl fentanyl [other name(s): 2-methyl-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide]	9827-(4-2017)
(Q) Ocfentanil [other name(s): N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide]	9838-(4-2017)
(R) 4-methoxy butyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide]	(4-2017)
(S) Para-fluorobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide]	9823-(4-2017)
(T) Acryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide]	- 9811-(6-2020)
(U) 4-Fluoroisobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide]	- 9824-(6-2020)
(V) Tetrahydrofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl) N-phenyltetrahydrofuran-2-carboxamide]	
(W) Cyclopropyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl) N-phenylcyclopropanecarboxamide]	- - 9845-(4-2021)
(X) Methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide]	- 9825-(4-2021)
(Y) Ortho-fluorofentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide]	- 9816-(4-2021)
(Z) Crotonyl fentanyl [other name(s): (E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide]	- 9844-(5-2022)
(AA) Cyclopentyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl) N-phenylcyclopentanecarboxamide]	
(BB) Para-chloroisobutyryl fentanyl [other name(s): N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide]	- 9826-(5-2022)
(CC) Para-methoxybutyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide]	- 9837-(5-2022)
(DD) Beta-methyl fentanyl [other name(s): N-phenyl-N-(1-(2-phenylpropyl) piperidin-4-yl)propionamide]	
(EE) Beta'-phenyl fentanyl [other name: N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide]	,

	(FF) fluor	2'-Fluoro ortho-fluorofentanyl [other name(s): N-(1-(2-rophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide]	9855-(5-2022)
	(GG) pipe	4'-Methyl acetyl fentanyl [other name(s): N-(1-(4-methylphenethyl) ridin-4-yl)-N-phenylacetamide]	9819-(5-2022)
	(HH) (1-p)	Ortho-fluorobutyryl fentanyl [other name(s): N-(2-fluorophenyl)-N-henethylpiperidin-4-yl)butyramide]	9846-(5-2022)
		no-methyl acetylfentanyl [other name(s): N-(2-methylphenyl)-N-(1-methylpiperidin-4-yl)acetamide]	-9848-(5-2022)
		no-methyl methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(2-nylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide]	9820-(5-2022)
	(KK) pher	Para-methylfentanyl [other name(s): N-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)propionamide]	9817-(5-2022)
	(LL) pher	Phenyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-nylbenzamide]	9841-(5-2022)
	(MM) N-pl	Thiofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-nenylthiophene-2-carboxamide]	9839-(5-2022)
	(NN) yl)(p	Fentanyl carbamate [other name(s): ethyl(1-phenethylpiperidin-4-phenyl)carbamate]	9851-(5-2022)
	(OO) pher	Ortho-fluoroacryl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-nethylpiperidin-4-yl)acrylamide]	9852-(5-2022)
	(PP) N-(1	Ortho-fluoroisobutyryl fentanyl [other name(s): N-(2-fluorophenyl)-phenethylpiperidin-4-yl)isobutyramide]	9853-(5-2022)
	(QQ) (1-p)	Para-fluoro furanyl fentanyl [other name(s): N-(4-fluorophenyl)-N-henethylpiperidin-4-yl)furan-2-carboxamide]	9854-(5-2022)
(52)	Zipeprol		9873
(53)	Brorphin	e	9098
su ap A	omers, est bstance, r oproval is ct [21 U.S	dazole-opioid substances, their isomers, esters, ethers, salts and salts of ers and ethers. Benzimidazole-opioid substances includes any not otherwise listed or excepted, and for which no exemption or in effect under Section 505 of the Federal Food, Drug, and Cosmetic .C. 355], that structurally has benzimidazole ring with an ethylamine tion and benzyl group at its 2-position:	f
(i)	With o	or without substitution on the benzimidazole;	
(ii) With o	or without substitution at the ethylamine;	
(ii	i) With o	or without inclusion of the ethylamine in a cyclic structure;	
(iv	v) With o	or without substitution on the benzyl ring; or	
(v) With o	or without replacement of the benzyl ring with an aromatic ring.	
(v	i) Benzii	midazole-opioid substances shall include but are not limited to:	

	(A)4'-Hydroxy Nitazene;	
	(B) 5-Aminoisotonitazene;	
	(C) Butonitazene;	
	(D)Clonitazene;	9612 *
	(E) Etodesnitazene, [other name(s): Etazene];	
	(F) Etonitazene;	9624*
	(G) Flunitazene;	
	(H) Isotonitazene;	9614
	(I) Isotodesnitazene;	
	(J) Metodesnitazene;	
	(K) Metonitazene;	9757
	(L) N-Desethyl Etonitazene;	
	(M) N-Desethyl Isotonitazene;	
	(N) N-Piperidinyl Etonitazene [other name(s): Etonitazepipne];	
	(O) N-Pyrrolidino Etonitazene [other name(s): Etonitazepyne];	
	(P) N-Pyrrolidino Protonitazene; and	
	(Q) Protonitazene.	
sche	um derivatives: (Narcotic Drugs) Unless specifically excepted or unless liste	d in another
	dule, any of the following opium derivatives, its salts, isomers, and salts of isomers are salts, isomers, and salts of isomers is possible within the specianation:	mers whenever
desi	xistence of such salts, isomers, and salts of isomers is possible within the speci	mers whenever fic chemical
design (1)	existence of such salts, isomers, and salts of isomers is possible within the speci gnation:	mers whenever affic chemical 9319*
(1) A (2) A	existence of such salts, isomers, and salts of isomers is possible within the specing action: Acetorphine	mers whenever affic chemical 9319*
(1) A (2) A (3) I	existence of such salts, isomers, and salts of isomers is possible within the specing partion: Acetorphine	mers whenever affic chemical 9319* 9051* 9052*
(1) A (2) A (3) I (4) G	existence of such salts, isomers, and salts of isomers is possible within the specing gration: Acetorphine	mers whenever affic chemical 9319* 9051* 9052* 9070*
(1) A (2) A (3) I (4) ((5) (existence of such salts, isomers, and salts of isomers is possible within the specing property of the salts of isomers is possible within the salts of isomers is possible within the salts of the salts of isomers is possible within the salts of isomers is possibl	mers whenever affic chemical 9319* 9051* 9070* 9053*
(1) A (2) A (3) I (4) ((5) ((6) (Existence of such salts, isomers, and salts of isomers is possible within the specing pration: Acetorphine	mers whenever affic chemical 9319* 9051* 9070* 9053* 9054*
(1) A (2) A (3) I (4) C (5) C (6) C (7) I	Existence of such salts, isomers, and salts of isomers is possible within the specing pration: Acetorphine	mers whenever affic chemical 9319* 9051* 9052* 9070* 9053* 9055*
(1) A (2) A (3) H (4) G (5) G (6) G (7) H (8) H	Existence of such salts, isomers, and salts of isomers is possible within the specing property of the salts of isomers is possible within the salts of isomers is possible within the salts of the salts of isomers is possible within the salts of isomers is possible within the salts of isomers is possible within the sal	mers whenever affic chemical 9319* 9051* 9052* 9070* 9053* 9055* 9145*
(1) A (2) A (3) H (4) G (5) G (6) G (7) H (8) H	Existence of such salts, isomers, and salts of isomers is possible within the specing gration: Acetorphine	mers whenever affic chemical 9319* 9051* 9052* 9070* 9053* 9055* 9145* 9335*
(1) A (2) A (3) I (4) C (5) C (6) C (7) I (8) I (9) I	existence of such salts, isomers, and salts of isomers is possible within the specing gnation: Acetorphine	mers whenever affic chemical
(1) A (2) A (3) I (4) C (5) C (6) C (7) I (8) I (9) I (10)	Existence of such salts, isomers, and salts of isomers is possible within the specing gnation: Acetorphine	mers whenever affic chemical 9319*

(13)	Methyldesorphine	9302*
(14)	Methyldihydromorphine	9304*
(15)	Morphine methylbromide	9305*
(16)	Morphine methylsulfonate	9306*
(17)	Morphine-N-Oxide	9307*
(18)	Myrophine	9308*
(19)	Nicocodeine	9309*
(20)	Nicomorphine	9312*
(21)	Normorphine	9313*
(22)	Pholcodine	9314*
(23)	Thebacon	9315*
(24)	Mitragynine	(11-2015)
(25)	7-Hydroxymitragynine	(11-2015)
design geom	istence of such salts, isomers, and salts of isomers is possible within the specification (for purposes of this paragraph only, the term "isomer" includes the opticetric isomers):	
(1) ar	1	7240 (12 1002)
	pha-ethyltryptamine	7249-(12-1993)
	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET.	7249-(12-1993)
(2) 4-	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-	,
(2) 4-	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET.	,
	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391*
	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391* - 7392-(8-1995)
(3) 4-	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391* - 7392-(8-1995)
(3) 4-	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391* - 7392-(8-1995)
(3) 4-(4) 2,	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391* - 7392-(8-1995)
(3) 4-(4) 2,	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391* - 7392-(8-1995)
(3) 4- (4) 2,	Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET. bromo-2,5-dimethoxy-amphetamine	7391* - 7392-(8-1995) 7396* - 7399-(3-1988)

(7) 4	-methoxyamphetamine	· 7411*
	Some trade or other names: 4-methoxy-alpha- methylphenethylamine; paramethoxyamphetamine; PMA.	
(8) 5	-methoxy-3,4-methylenedioxy-amphetamine	· 7401*
(9) 4	-methyl-2,5-dimethoxyamphetamine	7395*
	Some trade and other names: 4-methyl-2,5-dimethoxy-alphamethylphenethylamine; "DOM"; and "STP".	
(10)	3,4-methylenedioxy amphetamine	· 7400*
(11)	3,4-methylenedioxymethamphetamine	7405-(10-1985)
	Some trade or other names: MDMA)	
(12)	3,4-methylenedioxy-N-ethylamphetamine	- 7404-(6-1990)
	Some trade or other names: N- ethy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA; MDE; MDEA.	
(13)	N-hydroxy-3,4-methylenedioxyamphetamine	- 7402-(6-1990)
	Some trade or other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy) phenethylamine; N-hydroxy MDA	
(14)	3,4,5-trimethoxy amphetamine	7390*
(15)	5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT	7431*(1-2011)
(16)	alpha-methyltryptamine	- 7432-(7-2005)
	Some trade or other names: AMT	
(17)	Bufotenine	· 7433*
	Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.	
(18)	Diethyltryptamine	· 7434*
	Some trade or other names: N,N-Diethyltryptamine;DET.	
(19)	Dimethyltryptamine	····· 7435*
	Some trade or other names: DMT	
(20)	5-methoxy-N,N-diisopropyltryptamine	- 7439-(7-2005)
	Some trade or other names: 5-MeO-DIPT.	
(21)	Ibogaine	· 7260*
	Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1',2': 1,2] azepino [5,4-b] indole; Tabernanthe iboga.	
(22)	Lysergic acid diethylamide	7315*

(23)	Mescaline	7381*
(24)	Parahexyl	- 7374-(7-1983)
	Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl.	
(25)	Peyote	7415*
	Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts. (Interprets 21 USC 812 (c), Schedule I (c) (12)).	
(26)	N-ethyl-3-piperidyl benzilate	7482*
(27)	N-methyl-3-piperidyl benzilate	7484*
(28)	Psilocybin	7437*
(29)	Psilocyn	7438*
(30)	Ethylamine Analog of phencyclidine	7455*
	Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE.	
(31)	Pyrrolidine Analog of phencyclidine	7458*
	Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP	
(32)	Thiophene Analog of phencyclidine	7470*
	Some trade or other names: 1-[1-(2-thienyl) cyclohexyl] Piperidine; 2-Thienyl analog of phencyclidine; TPCP; TCP.	
(33)	1-[1-(2-Thienyl)cylcohexyl]pyrrolidine	- 7473-(9-1989)
	Some other trade or other names: TCPy.	
(34)	N,N-Diallyl-5-Methoxytryptamine;	(6-2012)
	Some trade or other names: 5-MeO DALT; 5-Methoxy-DALT	
(35)	2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; 5C-NBOMe	
(36)	2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 5I-NBOMe	(8-2013)
(37)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E	7509-(11-2013)
(38)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D	7508-(11-2013)
(39)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C	7519-(11-2013)
(40)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I	7518-(11-2013)
(41)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-2	7385-(11-2013)

	(42)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-4	7532-(11-2013)
	(43)	2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H	7517-(11-2013)
	(44)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; 2C-N	7521-(11-2013)
	(45)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine; 2C-P	7524-(11-2013)
	(46) N	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; 25B-IBOMe	(9-2018)
		2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25B-	(11-2018)
	(48)	2-[[[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25I-NBOH	(11-2018)
	(49) 2:	2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 5E-NBOMe	(7-2019)
		2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25H-IBOMe	(7-2019)
	(51) N	2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]- phenol; 25C-	(7-2019)
	(52)	2-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25H-NBOH	(7-2019)
	(53)	1-(4-methoxyphenyl)-N-methylpropan-2-amine	- 1245-(5-2022)
		Some trade or other names: Para-methoxymethamphetamine; PMMA	
	(54)	2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one	7286
		Some trade or other names: Methoxetamine; MXE	
(e)	comp depre when	ressants: Unless specifically excepted or unless listed in another schedule, any recound, mixture, or preparation which contains any quantity of the following subsessant effect on the central nervous system, including its salts, isomers, and salts never the existence of such salts, isomers, and salts of isomers is possible within tical designation:	stances having a of isomers
	h _y aı	amma-hydroxybutyric acid [other name(s): GHB; gamma-hydroxybutyrate; 4-ydroxybutyrate; 4-hydroxydutanoic acid; sodium oxybate; sodium oxybutyrate] nd its known precursors and analogs. Precursors include but are not limited to: amma-butyrolactone	
	(2) N	Mecloqualone	2572*
	(3) N	lethaqualone	2565*
	es or ur th	senzodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, sters and ethers. Benzodiazepine substances includes any substance, not therwise listed or excepted, and for which no exemption or approval is in effect nder section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], nat structurally has a fused 1,4-diazepine and benzene ring structure with a henyl connected to the diazepine ring, with any substitution(s) or replacement(s	

on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Benzodiazepine substances shall include but are not limited to:

(i) Bromazolam:
٠,	- 1	, Bronnazonann,

(ii) Clonazolam;		(4-2021))
-----	---------------	--	----------	---

- (iii) Flualprazolam:-----(4-2021)
- (iv) Flubromazepam; -----(4-2021)
- (v) Flubromazolam; -----(4-2021)
- (vi) Phenazepam; -----(6-2012)
- (vii) Phenazolam [other name(s): Clobromazolam].
- (5) Thienodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Thienodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,4-diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Thienodiazepine substances shall include but are not limited to:
 - (i) Etizolam ----- (12-2014)

(f) Stimulants:

(1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

· · · ·	G .1 *	1007 (0 1000)
(1)	Cathinone	 1235-(3-1988)
(-)	Cummone	1233 (3 1)00)

- (ii) (<u>+</u>) CIS-4-Methylaminorex [(<u>+</u>)CIS-4,5-dihydro-4- methyl-5-phenyl-2- oxazolamine] ------ 1590-(6-1990)
- (iii) Fenethylline ------ 1503-(9-1981)
- (iv) N-Benzylpiperazine------ 7493-(1-2005) Some trade or other names: BZP, 1-Benzylpiperazine
- Some trade of other names. Ber, I Benefit protaction
- (v) N-ethylamphetamine ----- 1475-(6-1982)
- (vi) N-[1-(1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers ------ 9818-(2-1986)
- (vii) N-[1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropan-mide (thenylfentanyl), its optical isomers, salts and salts of isomers ------ 9834-(2-1986)

	(viii)	N,N-Dimethylamphetamine [other name(s): N,N,Alpha-trimethylbenzeneethanamine; N,N,Alpha-trimethylphenethylamine], its salts, optical isomers, and salts of optical isomers	- 1480-(2-1989)
	(ix)	Methcathinone (some other names: 2-Methylamine-Proprophenone, alpha (methylamino)- Proprophenone, 2 (methylamino)-1-phenylpropan-1-one, alpha-N-Methylaminopropiophenone, monomethylpropion, ephedrone, N methylcathinone, methycathinone, AL-464, AL-422, AL-463 and UR-1431), its salts, optical isomers and salts of optical isomers	
	(x)	Aminorex [other name(s): aminoraphen, 2-amino-5 phenyl-2-oxazoline, or 4,5 dihyrdo-5-phenyl-2-oxazolamine], its salts, optical isomers, and salts of optical isomers	1585-(12-1993)
	(xi)	4,4'-Dimethylaminorex some other names: 4,4'-DMAR, 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine, or 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine	- 1595-(5-2022)
	(xii)	Amineptine	1219
	(xiii)	Mesocarb	1227
	(xiv)	Methyl-N-ethylcathinone (MEC)	(6-2014)
	(xv)	Methiopropamine. [other name(s): N-methyl-1-(thiophen-2-yl)propan-2-amine]	1478
(2)	indire chem conta follo existe speci	material, compound, mixture, or preparation, whether produced directly or ectly from a substance of vegetable origin or independently by means of call synthesis or by a combination of extraction and chemical synthesis, that any quantity of the following substances, or that contains any of the wing substances' analogs, salts, isomers, and salts of isomers when the ence of the analogs, salts, isomers, and salts of isomers is possible within the fic chemical designation, with the following chemical structure is included in dule I:	
	(i)	4-Methylmethcathinone (Mephedrone)	1248-(3-2011)
	(ii)	Methylenedioxypyrovalerone (MDPV)	(3-2011)
	(iii)	3,4-Methylenedioxy-N-methylcathinone (Methylone	- 7540-(3-2011)
	(iv)	4-Methoxymethcathinone	(3-2011)
	(v)	3-Fluoromethcathinone	(3-2011)
	(vi)	4-Fluoromethcathinone	(3-2011)
	(vii)	1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one-(Butylone)	7541-(11-2014)
	(viii)	Alpha-Pyrrolidinopentiophenone (Alpha-PVP)	7545-(11-2015)
	(ix)	4-methyl-N-ethylcathinone (4-MEC)	1249-(9-2018)
	(x)	4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP)	7498-(9-2018)
	(xi)	2-(methylamino)-1-phenylpentan-1-one (Pentedrone)	1246-(9-2018)

(:	(XII) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone; bk-MBDP)	7542-(9-2018)
(:	(xiii) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone)	` /
	(xiv) 3-fluoro-N-methylcathinone (3-FMC)	
(:	(xv) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Naphyrone)	1258-(9-2018)
(:	(xvi) Alpha-pyrrolidinobutiophenone ([Alpha]-PBP)	7546-(9-2018)
(:	(xvii)A compound, unless listed in another schedule or a legend drug, that is structurally derived from 2-Amino-phenyl-1-propanone by modification or by substitution:	(3-2012)
	(A) In the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one (1) or more other univalent substituents;	
	(B) At the 3-position with an alkyl substituent; or	
	(C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.	
((xviii) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (N-Ethylpentylone)	7543-(7-2019)
(:	(xix) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)	7547-(4-2021)
((xx) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone (Eutylone)	7549-(4-2021)
(:	(xxi) 2-(ethylamino)-1-phenylhexan-1-one [other name(s): (N-Ethylhexedrone; Alpha-Ethylaminohexanophenone)]	7246
(:	(xxii) 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (Alpha-Pyrrolidinohexanophenone; Alpha-PHP)]	7544
	(xxiii) 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one [other name(s): (4-	
(:	Methyl-alpha-ethylaminopentiophenone; 4-MEAP)]	7245
	Methyl-alpha-ethylaminopentiophenone; 4-MEAP)](xxiv) 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (4'-Methyl-alpha-pyrrolidinohexiophenone; MPHP)]	
(:	(xxiv) 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (4'-	7446
(:	(xxiv) 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (4'-Methyl-alpha-pyrrolidinohexiophenone; MPHP)](xxv)1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one [other name(s): (Alpha-	7446 7548

SCHEDULE II

- (a) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.
- (b) Narcotic Drugs: Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or

indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β-naltrexol, naltrexone and samidorphan, and their respective salts, but including the following:

(i) Raw opium 9600*
(ii) Opium extracts 9610*
(iii) Opium fluid extracts 9620*
(iv) Powdered opium 9639*
(v) Granulated opium 9640*
(vi) Tincture of opium 9630*
(vii) Codeine 9050*
(viii) Dihydroetorphine 9334*
(ix) Ethylmorphine 9190*
(x) Etorphine hydrochloride 9059*
(xi) Hydrocodone 9193*
(xii) Hydromorphone 9150*
(xiii) Metopon 9260*
(xiv) Morphine 9300*
(xv) Oripavine 9330*(9-2007)
(xvi) Oxycodone 9143*
(xvii)Oxymorphone 9652*
(xviii) Thebaine 9333*
(xix) Tapentadol 9780-(5-2009)
(xx) Noroxymorphone 9668-(4-2021)

- (2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.*
- (3) Opium poppy and poppy straw.*
- (4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound,

any of these substances, except that the substances shall not include	
(i) Decocainized coca leaves or extraction of coca leaves, which not contain cocaine or ecgonine;	h extractions do
(ii) [123I]ioflupane; or	
(iii) [¹⁸ F]FP–CIT.	
(5) Concentrate or poppy straw (the crude extract of poppy straw in eigen solid or powder form which contains the phenanthrene alkaloids o poppy),	f the opium
c) Opiates: (Narcotic Drugs) Unless specifically excepted or unless in following opiates, including its isomers, esters, ethers, salts, and salts whenever the existence of such isomers, esters, ethers, and salts is poschemical designations:	of isomers, esters and ethers
(1) Alfentanil	9737-(2-1987)
(2) Alphaprodine	9010*
(3) Anileridine	9020*
(4) Bezitramide	9800*
(5) Bulk Dextropropoxyphene (non-dosage forms)	9273-(9-1981)
(6) Carfentanil	9743-(9-1988)
(7) Dihydrocodeine	9120*
(8) Diphenoxylate	9170*
(9) Fentanyl	9801*
(10) Isomethadone	9226*
(11) Levo-alphacetylmethadol (LAAM)	9648-(12-1993)
(12) Levomethorphan	9210*
(13) Levorphanol	9220*
(14) Metazocine	9240*
(15) Methadone	9250*
(16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-dipher	nyl butane 9254*
(17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylp	propane-
carboxylic acid	
(18) Pethidine (Meperidine)	
(19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidin	e 9232*
(20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxyla	ate 9233*

	(21)	Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic aci	d 9234*
	(22)	Phenazocine	9715*
	(23)	Piminodine	9730*
	(24)	Racemethorphan	9732*
	(25)	Racemorphan	9733*
	(26)	Remifentanil	9739-(11-1996)
	(27)	Sufentanil	9740-(9-1981)
	(28)	Thiafentanil	9729-(4-2021)
	(29)	Oliceridine	9245-(5-2022)
	(30)	Tianeptine	(5-2022)
(d) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system:			g substances having a
	` ′	mphetamine, its salts, optical isomers, and salts of its optical isomers lethamphetamine, its salts, isomers, and salts of its isomers	
		isdexamefetamine	
	` /	nenmetrazine and its salts	` '
		lethylphenidate	
(e)	composition depression when the	essants: Unless specifically excepted or unless listed in another schedule, ound, mixture, or preparation which contains any quantity of the following sant effect on the central nervous system, including its salts, isomers, and ever the existence of such salts, isomers, and salts of isomers is possible with designation:	g substances having a l salts of isomers
	(1) A	mobarbital	2125*
	(2) G	lutethimide	2550-(2-1991)
	(3) Pe	entobarbital	2270*
	(4) Pł	nencyclidine	7471*
	(5) Se	ecobarbital	2315*
(f)	Hallu	icinogenic Substances:	
	(1) N	abilone	7379-(11-1987)
		[Other name(s) for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one].	0,10a-

	U.S.	nabinol in an oral solution in a drug product approved for marketing by the . Food and Drug Administration; [(-)-delta-9-trans-hydrocannabinol(delta-9-THC)]	7365-(7-2019)
(g)		iate Precursor: Unless specifically excepted or unless listed in another schedul, compound, mixture, or preparation which contains any quantity of the followies:	
	(1) Imn	nediate precursor to Amphetamine and Methamphetamine:	
	(i)	Phenylacetone	8501-(3-1980)
		Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl Ketone; methyl benzyl Ketone.	
	(2) Imm	nediate precursor to Phencyclidine (PCP):	
	(i)	1-phenylcyclohexylamine	7460*
	(ii)	1-piperidinocyclohexanecarbonitrile (PCC)	8603*
	(3) Imn	nediate precursor to Fentanyl:	
	(i)	4-anilino-N-phenethylpiperidine (ANPP)	8333*(8-2010)
	(ii)	N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)	8366-(4-2021)
<u>SC</u>	<u>HEDUL</u>	<u>LE III</u>	
(a)	usual na	le III shall consist of the drugs and other substances, by whatever official name ame, chemical name, or brand name designated, listed in this section. Each drug assigned the DEA Controlled Substances Code Number set forth opposite it.	
(b)	compou stimular or geom	ants: Unless specifically excepted or unless listed in another schedule, any maind, mixture, or preparation which contains any quantity of the following substant effect on the central nervous system, including its salts, isomers (whether opnetric), and salts of such isomers whenever the existence of such salts, isomers, is possible within the specific chemical designation:	ances having a tical, position,
	stim prep Sect list	ose compounds, mixtures, or preparations in dosage unit form containing any culant substances listed in Schedule II which compounds, mixtures, or parations were listed on August 25, 1971, as excepted compounds under tion 308.32, and any other drug of the quantitative composition shown in that for those drugs or which is the same except that it contains a lesser quantity of trolled substances————————————————————————————————————	
	(2) Ben	zphetamine	1228*
	(3) Chlo	orphentermine	1645*
	(4) Clo	rtermine	1647*
	(5) Phe	ndimetrazine	1615*

(c)	e) Depressants : Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having depressant effect on the central nervous system:			•
	(1)	Any	compound, mixture, or preparation containing:	
		(i)	Amobarbital	2126*
		(ii)	Secobarbital	2316*
		(iii)	Pentobarbital	2271*
		(iv)	Embutramide	2020*(9-2006)
			or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.	
	(2)	Any	suppository dosage form containing:	
		(i)	Amobarbital	2126*
		(ii)	Secobarbital	2316*
		(iii)	Pentobarbital	2271*
			or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.	
	(3)		substance which contains any quantity of a derivative of barbituric acid or salt thereof	2100*
	(4)	Chlo	orhexadol	2510*
	(5)	isom	drug product containing gamma hydroxybutyric acid, including its salts, ners, and salts of isomers, for which an application is approved under section of the Federal Food, Drug, and Cosmetic Act	- 2012-(2-2001)
	(6)		mine. its salts, isomers, and salts of isomers	
	(0)	S	ome other names for Ketamine: (+-)-2-(2-Chlorophenyl)-2-(Methylamino)-yclohexanone.	7203 (7 1999)
	(7)	Lyse	ergic acid	7300*
	(8)	Lyse	ergic acid amide	7310*
	(9)	Metl	nyprylon	2575*
	(10) S	ulfondiethylmethane	2600*
	(11) S	ulfonethylmethane	2605*
	(12) S	ulfonmethane	2610*
	(13) T	iletamine and zolazepam or any salt thereof	- 7295-(3-1988)
		S	ome trade or other name for a tiletamine- zolazepam combination product: elazol.	

			Some trade or other names for tiletamine: -2(ethylamino)-2-(2-thienyl)-cyclohexanone.	
			Some trade or other names for zolazepam: -4(2-fluorophenyl)-6,8-dihydro-3,8,-trimethylpyrazolo-[3,4-e] [1,4,]-diazepin-7(1-H)-one. flupyrazapon.	
	(14) I	Perampanel	2261-(11-2013)
(d)	Na	lorp	nine	9400*
(e)	Na	arco	tic drugs: Unless specifically excepted or unless listed in another schedule:	
	(1)	nar	y material, compound, mixture, or preparation containing any of the following cotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in ited quantities as set forth below:	5
		(i)	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium	9803*
		(ii)	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts	9804*
		(iii)	Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts	9807*
		(iv)	Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts	9808*
		(v)	Not more than 500 milligrams of opium per 100 milliliters or per 100 gram or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts	
		(vi)	Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts	9810*
	(2)	-	y material, compound, mixture, or preparation containing any of the following cotic drugs or their salts, as set forth below:	5
		(i)	Buprenorphine (10-02 Transfer)	- 9064-(6-1985)
		(ii)	Reserved	
(f)	cor salt	npoi ts, is	ic Steroids: Unless specifically excepted or unless listed in another schedule, and, mixture, or preparation containing any quantity of the following substant omers, and salts of isomers whenever the existence of such salts of isomers is cific chemical designation:	es, including its possible within

(1) Boldenone;(9-19			
(2) Boldione;			
(3) Chlorotestosterone (4-chlortestosterone);(9			
(4) Clostebol;	(9-1991)		
(5) Dehydrochlormethyltestosterone;	(9-1991)		
(6) Desoxymethyltestosterone	(1-2010)		
(7) Dihydrotestosterone (4-dihydrotestosterone);	(9-1991)		
(8) Drostanolone;	(9-1991)		
(9) Ethylestrenol;	(9-1991)		
(10) Fluoxymesterone;	(9-1991)		
(11) Formebulone (formebolone);	(9-1991)		
(12) Mesterolone;	(9-1991)		
(13) Methandienone, also known as Methandrostenolone;	(9-1991)		
(14) Methandranone;	(9-1991)		
(15) Methandriol;	(9-1991)		
(16) Methenolone;	(9-1991)		
(17) Methyltestosterone;	(9-1991)		
(18) Mibolerone;	(9-1991)		
(19) Nandrolone;	(9-1991)		
(20) 19-Nor-4,9(10)-Androstadienedione	(1-2010)		
(21) Norethandrolone;	(9-1991)		
(22) Oxandrolone;	(9-1991)		
(23) Oxymesterone;	(9-1991)		
(24) Oxymetholone;	(9-1991)		
(25) Stanolone;	(9-1991)		
(26) Stanozolol;	(9-1991)		
(27) Testolactone;	(9-1991)		
(28) Testosterone;	(9-1991)		
(29) Trenbolone	(9-1991)		
(30) Prostanozol	(8-2012)		
(31) Methasterone	(8-2012);		
and			

general content (9-1991)	(32)	Any salt, ester, or isomer of a drug or substance described or list in this			
NDC Number 0536-1605	pa	aragraph, if that salt, ester, or isomer promotes muscle growth	(9-1991)		
(1) Andro-Estro 90-4 0536-1605 (2) Androgyn L.A 0456-1005 (3) Component E-H in Process Pellets Ivy Labs Inc. (4) Component E-H in Process Granulation Ivy Labs Inc. (5) Component TE-S in process Pellets Ivy Labs Inc. (6) Component TE-S in process Pellets Ivy Labs Inc. (7) depANDROGYN 0456-1020 (8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Estratest 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) <t< td=""><td colspan="5"></td></t<>					
(2) Androgyn L.A 0456-1005 (3) Component E-H in Process Pellets Ivy Labs Inc. (4) Component E-H in Process Granulation Ivy Labs Inc. (5) Component TE-S in process Granulation Ivy Labs Inc. (6) Component TE-S in process Pellets Ivy Labs Inc. (7) depANDROGYN 0456-1020 (8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Estratest 0032-1026 (21) Estratest HS 0032-1026 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA		NDC Number			
(3) Component E-H in Process Pellets Ivy Labs Inc. (4) Component E-H in Process Granulation Ivy Labs Inc. (5) Component TE-S in process Granulation Ivy Labs Inc. (6) Component TE-S in process Pellets Ivy Labs Inc. (7) depANDROGYN -0456-1020 (8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) ANDAPharm (19) Estratest 0032-1023 (21) Estratest HS 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (25) Methyltestosterone & Est	(1) A	ndro-Estro 90-4	0536-1605		
(4) Component E-H in Process Granulation Ivy Labs Inc (5) Component TE-S in process Granulation Ivy Labs Inc (6) Component TE-S in process Pellets Ivy Labs Inc (7) depANDROGYN -0456-1020 (8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) ANDAPharm (19) Estratest 0032-1026 (21) Estratest HS 0032-1026 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (Laif Strength) (1.25mg/0.625mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175	(2) A	ndrogyn L.A	0456-1005		
(5) Component TE-S in process Granulation Ivy Labs Inc (6) Component TE-S in process Pellets Ivy Labs Inc (7) depANDROGYN 0456-1020 (8) Depo-Tcstadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Estratest 0032-1026 (21) Estratest HS 0032-1026 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879 <td>(3) C</td> <td>omponent E-H in Process Pellets</td> <td> Ivy Labs Inc.</td>	(3) C	omponent E-H in Process Pellets	Ivy Labs Inc.		
(6) Component TE-S in process Pellets Ivy Labs Inc (7) depANDROGYN 0456-1020 (8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Estratest 0032-1026 ANDAPharm (20) Estratest HS 0032-1026 032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(4) C	omponent E-H in Process Granulation	Ivy Labs Inc		
(7) depANDROGYN 0456-1020 (8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (USP (1.25mg/2.5mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) ANDAPharm (19) Estraftest HS 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(5) C	omponent TE-S in process Granulation	Ivy Labs Inc		
(8) Depo-Testadiol 0009-0253 (9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) ANDAPharm (19) Estratified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet ANDAPharm (20) Estratest 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(6) C	omponent TE-S in process Pellets	Ivy Labs Inc		
(9) DEPO-T.E 52765-257 (10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Estratest 0032-1026 ANDAPharm (20) Estratest HS 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(7) de	epANDROGYN	0456-1020		
(10) depTESTROGEN 51698-257 (11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Essian H.S Pharmaceutics (16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone (USP (1.25mg/2.5mg) ANDAPharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Estratest Methyltestosterone (1.25mg/2.5mg) Tablet ANDAPharm (20) Estratest 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(8) D	epo-Testadiol	0009-0253		
(11) Duomone 52047-360 (12) DUO-SPAN II 0684-0102 (13) DURATESTRIN 43797-016 (14) Essian Pharmaceutics (15) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) Interpharm (17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet ANDAPharm (20) Estratest 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(9) D	EPO-T.E	52765-257		
(12) DUO-SPAN II	(10)	depTESTROGEN	51698-257		
(13) DURATESTRIN	(11)	Duomone	52047-360		
(14) Essian	(12)	DUO-SPAN II	0684-0102		
(15) Essian H.S	(13)	DURATESTRIN	43797-016		
(16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg)	(14)	Essian	Pharmaceutics		
(17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) Interpharm (18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet ANDAPharm (19) Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet ANDAPharm (20) Estratest 0032-1026 (21) Estratest HS 0032-1023 (22) Menogen 59243-570 (23) Menogen HS 59243-560 (24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(15)	Essian H.S	Pharmaceutics		
(18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet	(16)	Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg)	Interpharm		
(19) Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet	(17)	Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg)	Interpharm		
(20) Estratest ————————————————————————————————————	(18)	Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet	ANDAPharm		
(21) Estratest HS	(19)	Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet	ANDAPharm		
(22) Menogen	(20)	Estratest	0032-1026		
(23) Menogen HS	(21)	Estratest HS	0032-1023		
(24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) Lannett Co (25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST	(22)	Menogen	59243-570		
(25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) Lannett Co (26) PAN ESTRA TEST	(23)	Menogen HS	59243-560		
(26) PAN ESTRA TEST 0525-0175 (27) Premarin with Methyltestosterone 0046-0879	(24)	Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg)	Lannett Co		
(27) Premarin with Methyltestosterone 0046-0879	(25)	Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625	img) Lannett Co		
	(26)	PAN ESTRA TEST	0525-0175		
(28) Premarin with Methyltestosterone 0046-0878	(27)	Premarin with Methyltestosterone	0046-0879		
	(28)	Premarin with Methyltestosterone	0046-0878		

(29)	Syntest D.S	66576-231
(30)	Stntest H.S	66576-230
(31)	Synovex H in process bulk pellets	Syntex Animal
(32)	Synovex H in process granulation	Syntex Animal
(33)	Synovex Plus in process granulation	Fort Dodge
(34)	Synovex Plus in process bulk pellets	Fort Dodge
(35)	TEST-ESTRO Cypionates	0536-9470
(36)	Testoderm with Adhesive 4mg/d	Alza Corp
(37)	Testoderm 4mg/d	17314-4608
(38)	Testoderm 6mg/d	17314-4609
(39)	Testoderm with Adhesive 6mg/d	17314-2836
(40)	Testoderm in process film	Alza Corp
(41)	Testoderm with Adhesive in process film	Alza Corp
(42)	Testosterone Cypionate/Estradiol Cypionate injection	54274-530
(43)	Testosterone Cypionate/Estradiol Cypionate injection	0182-3069
(44)	Testosterone Cyp 50 Estradiol Cyp 2	0814-7737
(45)	Testosterone Cypionate/Estradiol Cypionate injection	0364-6611
(46)	Testosterone Cypionate/Estradiol Cypionate injection	0402-0257
(47)	Testosterone Enanthate/Estradiol Valerate injection	0182-3073
(48)	Testosterone Enanthate/Estradiol Valerate injection	0364-6618
(49)	Testosterone Enanthate/Estradiol Valerate injection	0402-0360
(50)	Testosterone Ophthalmic Solution	Allergan
(51)	Tilapia Sex Reversal Feed (investigational	Ranger, Inc
	rinary Anabolic Steroid Implant Products: Anabolic steroid products expr nistration through implants in cattle or other nonhuman species exempted NDC/DIN	
(1) C	omponent E-H	021641-002
(2) C	omponent E-H	01968327
(3) C	omponent TE-S	021641-004
(4) C	omponent T-H	0211641-006
(5) C	omponent T-S	0211641-005
(6) F	-TO	00093351

(7) F	inaplix-H	- 12799-807-10
(8) F	inaplix-S	- 12799-807-07
(9) H	leifer-old	Boehringer
(10)	Heifer-old	Ingelheim
(11)	Heifer-old	Ivy Lab.
(12)	Implus-H	- 0009-0434-01
(13)	Implus-H	06-0434-01
	01968327	
(14)	Masculinizing Feed for Fish (Invesitigational)	Rangen,Inc.
(14)(15)	Masculinizing Feed for Fish (Invesitigational)	_
` /	· · · · · · · · · · · · · · · · · · ·	12799-811
(15)	Revalor-G	12799-811 12799-810
(15) (16)	Revalor-H	12799-811 12799-810 12799-809
(15) (16) (17)	Revalor-G	12799-811 12799-810 12799-809 0856-3901
(15) (16) (17) (18)	Revalor-G Revalor-H Synovex H	12799-811 12799-810 12799-809 0856-3901 Syntex

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

(i) Hallucinogenic substances:

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product ----- 7369-(11-1987)

[Some other names for dronabinol: (6a R-trans)-6a,7,8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo [b,d] phyran-1-ol, or (-)-delta 9-(trans)-tetrahydrocannabinol]

SCHEDULE IV

- (a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) <u>Narcotic drugs</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

		ot more than 1 milligram of difenoxin and not less than 25 micrograms of cropine sulfate per dosage unit	9167*
		vextro propoxyphene (alpha-(+)-4-dimethylamino- 1,2-diphenyl-3-methyl-2-ropionoxybutane)	9278-(11-1987)
(c)	comp	essants: Unless specifically excepted or unless listed in another schedule, any bound, mixture, or preparation which contains any quantity of the following suding its salts, isomers, and salts of isomers whenever the existence of such salt of isomers is possible within the specific chemical designation:	bstances,
	(1) A	lprazolam	2882-(6-1982)
	(2) B	arbital	2145*
	(3) B	romazepam	2748-(1-1985)
	(4) C	amazepam	2749-(1-1985)
	(5) C	hloral betaine	2460*
	(6) C	hloral hydrate	2465*
	(7) C	hlordiazepoxide	2744*
	(8) C	lobazam	2751-(1-1985)
	(9) C	lonazepam	2737*
	(10)	Clorazepate	2768*
	(11)	Clotiazepam	2752-(1-1985)
	(12)	Cloxazolam	2753-(1-1985)
	(13)	Delorazepam	2754-(1-1985)
	(14)	Diazepam	2765*
	(15)	Dichloralphenazone	- 2467-(10-2002)
	(16)	Estazolam	2756-(1-1985)
	(17)	Ethchlorvynol	2540*
	(18)	Ethinamate	2545*
	(19)	Ethyl loflazepate	2758-(1-1985)
	(20)	Fludiazepam	2759-(1-1985)
	(21)	Flunitrazepam	2763-(1-1985)
	(22)	Flurazepam	2767*
	(23)	Fospropofol	- 2138-(11-2009)
	(24)	Halazepam	2762-(6-1982)
	(25)	Haloxazolam	2771-(1-1985)

(26)	Ketazolam	2772-(1-1985)
(27)	Loprazolam	2773-(1-1985)
(28)	Lorazepam	2885*
(29)	Lormetazepam	2774-(1-1985)
(30)	Mebutamate	2800*
(31)	Medazepam	2836-(1-1985)
(32)	Meprobamate	2820*
(33)	Methohexital	2264*
(34)	Methylphenobarbital (mephorbarbital)	2250*
(35)	Midazolam	2884-(1-1985)
(36)	Nimetazepam	2837-(1-1985)
(37)	Nitrazepam	2834-(1-1985)
(38)	Nordiazepam	2838-(1-1985)
(39)	Oxazepam	2835*
(40)	Oxazolam	2839*
(41)	Paraldehyde	2585*
(42)	Petrichloral	2591*
(43)	Phenobarbital	2285*
(44)	Pinazepam	2883-(1-1985)
(45)	Prazepam	2764*
(46)	Quazepam	2881-(11-1986)
(47)	Temazepam	2925-(9-1981)
(48)	Tetrazepam	2886-(1-1985)
(49)	Triazolam	2887-(7-1983)
(50)	Zaleplon	2781-(9-1999)
(51)	Zolpidem	2783-(12-1993)
(52)	Zopiclone	2784-(1-2006)
(53)	Alfaxalone	2731-(2-2014)
(54)	Carisoprodol	8192-(4-1997)
(55)	Tramadol	9752-(8-2007)
(56)	Suvorexant	2223-(8-2014)
(57)	Brexanolone	2400-(4-2021)
(58)	Lemborexant	2245-(4-2021)

(59) Remimazolam	2846-(5-2022)	
(60) Daridorexant	2410	
(d) <u>Stimulants</u> : Unless specifically excepted or unless listed in another schedule, compound, mixture, or preparation which contains any quantity of the followin stimulant effect on the central nervous system, including its salts, isomers (when or geometric), and salts of such isomers whenever the existence of such salts, is isomers is possible within the specific chemical designation:	g substances having a ether optical, position,	
(1) Cathine ((+)-Norpseudeophedrine	1230-(3-1988)	
(2) Diethylpropion	1610*	
(3) Fencamfamin	1760-(3-1988)	
(4) Fenproporex	1575-(3-1988)	
(5) Lorcaserin	1625-(6-2013)	
(6) Mazindol	1605-(6-1982)	
(7) Mefenorex	1580-(3-1988)	
(8) Modafinil	1680-(1-1999)	
(9) Pemoline (including organometallic complexes and chelates thereof)	1530*	
(10) Phentermine	1640*	
(11) Pipradrol	1750-(9-1981)	
(12) Serdexmethylphenidate	1729	
(13) Sibutramine	1675-(2-1998)	
(14) Solriamfetol	1650-(4-2021)	
(15) SPA ((-)-1-dimethylamino-1,2,diphenylethane)	1635-(9-1981)	
(e) Other substances: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:		
(1) Pentazocine	9709-(4-1979)	
(2) Butorphanol	9720-(4-1997)	
(3) Nalbuphine	(4-1997)	
(4) Eluxadoline	9725-(4-2017)	

SCHEDULE V

(a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) **Narcotic Drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

Reserved

(c) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams*
(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams*
(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams*
(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit*
(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams*
(6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit*
(d) <u>Stimulants</u> : unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
(1) Pyrovalerone 1485-(3-1988)
(2) Ephedrine:a -{-(Methylamino)ethyl}benzene-methanol;(10-1995)
a-{-(methylamino) ethyl} benzyl alcohol; 2-methylamino-1-phenyl-1-propanol; 1-phenyl-1-hydroxy-2-methylaminopropane; 1-phenyl-2-methylaminopropanol; a - hydroxy-b-methylaminopropylbenzene; a product which occurs in the Chinese herb Ma Huang (Ephedra vulgaris, Ephedra sinica Stapf., Ephedra equisetina Bunge, Gnetaceae) in several other Ephedra spp.
(3) Phenylpropanolamine(7-2005)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(4) Pseudoephedrine ----- (7-2005)

(e)	Depressants: Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:			
	(1) Preg	abalin [(S)-3-(aminomethyl)-5-methylhexanoic acid	- 2782-(1-2006)	
	(2) Laco	osamide	- 2746-(5-2009)	
	(3) Briv	aracetam	- 2710-(4-2017)	
	(4) Lasr	niditan	- 2790-(4-2021)	
	(5) Cend	obamate	- 2720-(4-2021)	
	(6) Gana	axolone	2401	
(f)	Other s	substances:		
	(1) Non	e.		
<u>SC</u>	HEDUL	E VI ****		
	by a con substance salts, isc Schedule	y from a substance of vegetable origin or independently by means of chemical subination of extraction and chemical synthesis, that contains any quantity of tees, or that contains any of their salts, isomers, and salts of isomers when the omers, and salts of isomers is possible within the specific chemical designation eVI:	the following existence of the in, is included in	
	(2) Tetra	ahydrocannabinols, unless the tetrahydrocannabinol is:	**	
	(i)	Contained in hemp-derived cannabidiol;		
	(ii)	Not more than three-tenths of one percent (0.3%) of delta-9 tetrahydrocannabinol in the hemp-derived cannabidiol on a dry weight basis as verified by a nationally accredited laboratory for quality, purity and accuracy standards; and	(6-2020) ***	
	(iii)	Not approved by the United States Food and Drug Administration for marketing as a medication;	(6-2020)	
	(3) A sy	enthetic equivalent of:		
	(i)	The substance contained in the Cannabis plant; or	**	
	(ii)	The substance contained in the resinous extractives of the genus Cannabis;	**	
	class the p	ia divinorum or Salvinorin A, which includes all parts of the plant presently sified botanically as Salvia divinorum, whether growing or not, the seeds of plant, any extract from any part of the plant, and every compound, ufacture, derivative, mixture, or preparation of the plant, its seeds, or its		

	salts, ison	ncluding salts, isomers, and salts of isomers when the existence of the ners, and salts of isomers is possible within the specific chemical n;	**
(5)	classes de specific un Compoun numerical	substances, derivatives, or their isomers in the chemical structural scribed below in subdivisions $(a)(5)(i)-(a)(5)(x)$ of this section and also nclassified substances in subdivision $(a)(5)(xi)$ of this section. ds of the structures described in this subdivision $(a)(5)$, regardless of designation of atomic positions, are included in this subdivision $(a)(5)$. etic substances, derivatives, or their isomers included in this subdivision	
	(i) Tetr	ahydrocannabinols:	
	(A) Te	trahydrocannabinols, including without limitation the following:	**
	a)	Delta-1 cis or trans tetrahydrocannabinol [other name(s): Delta-9 cis or trans tetrahydrocannabinol], and its optical isomers;	**
	b)	Delta-6 cis or trans tetrahydrocannabinol [other name(s): Delta-8 cis or trans tetrahydrocannabinol], and its optical isomers;	**
	c)	Delta- 3,4 cis or trans tetrahydrocannabinol [other name(s): Delta-6a,10a cis or trans tetrahydrocannabinol], and its optical isomers;	**
	d)	Delta-10 cis or trans tetrahydrocannabinol, and its optical isomers;	***
	e)	Delta-8 tetrahydrocannabinol acetate ester;	***
	f)	Delta-9 tetrahydrocannabinol acetate ester;	***
	g)	Delta-6a,10a, tetrahydrocannabinol acetate ester;	
	h)	Delta-10 tetrahydrocannabinol acetate ester; and,	***
	i)	A product derived from industrial hemp that was produced as a result of a synthetic chemical process that converted the industrial hemp or a substance contained in industrial hemp into Delta-8, Delta-9, Delta 6a,10a, or Delta-10 tetrahydrocannabinol including their respective acetate esters.	***
	dr Ac	onabinol in sesame oil and encapsulated in a soft gelatin capsule in a ag product approved by the United States Food and Drug Iministration is not a tetrahydrocannabinol under this subdivision (5)(i);	**
	na the cy (4- ine rin	hthoylindoles, or any compound structurally derived from 3-(1-phthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at a nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-morpholinyl)ethyl group, whether or not further substituted in the dole ring to any extent and whether or not substituted in the naphthyl g to any extent, including without limitation the following:	
	(A)JV	/H-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;	**

((B) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole;	**
((C) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole;	
((D) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole;	**
((E) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole;	**
((F) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole;	**
((G) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;	**
((H) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl) indole;	**
((I) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;	**
((J) JWH-200, or 1-[2-(4-morpholiny)ethyl]-3-(1-naphthoyl) indole;	**
((K) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl) indole;	**
((L) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole;	**
((M) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;	**
((N) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone;	**
((O) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone; and	**
((P) THJ-2201, or [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone;7	024-(7-2019)
(iii)	Naphthylmethylindoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following:	**
((A) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and	**
((B) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane;	**
(iv)	Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone;	**
(v)	Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-	

methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane;	**
(vi) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:	**
(A) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone;	**
(B) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetyl)indole;	**
(C) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole;	
(D) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl) indole; and	**
(E) RCS-8, or 1-(2-cyclohexylethyl)-3-(2- methoxyphenylacetyl)indole;	**
(vii) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following:	**
(A) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;	**
(B) Cannabicyclohexanol or CP 47,497 C8 homologue, or 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; and	**
(C) CP 55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol;	**
(viii) Benzoylindoles, or any compound structurally derived from a 3- (benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:	**
(A) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;	**
(B) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole;	**
(C) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y]methanone;	**

	(D) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; and	**
	(E) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-butyl-1H-indol-3-yl)-methanone;	**
(ix)	Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantly ring to any extent, including without limitation the following:	**
	(A) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone;	**
	(B) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone;	**
	(C) JWH-018 adamantyl carboxamide, or 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide [other name(s): 2NE1, moved in Schedule VI in 2020]	**
	(D) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3-carboxamide;	**
	(E) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide	7049**
	(F) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3-carboxamide;	**
(x)	Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl,haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following:	**
	(A) UR-144, or (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone;	**
	(B) XLR-11, or [1-(5-fluoropentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone;	**
	(C) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;	**
	(D) 5-Chloro-UR-144, or ([-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone:	**

	(E)) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and	**
	(F)	A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone;	**
(xi) (Unclassified Synthetic Cannabinoids, including without limitation the following:	**
	(A)	CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] Acetate;	**
	(B)) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;	**
	(C)	HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;	**
	(D) Dimethylheptylpyran or DMHP;	**
	(E)) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone;	**
	(F)) URB597, or [3-(3-carbamoylphenyl)phenyl] N-Cyclohexylcarbamate;	**
	(G	URB754, or 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one;	**
	(H	() CB-13, or 1-naphthalenyl[4-(pentyloxy)-1 naphthalenyl]-methanone;	**
		a) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate;	**
	(I)	PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3-carboxylate;	**
	(J)	5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;	**
	(K	BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate;	**
	(L)) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; -	**
	(M	I) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide;	**
	(N	7) 5-Fluoro-AMB, or n-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester	7033-(9-2018)
	(O)	MMB-CHMICA,or methyl-(1-cyclohexylmethyl)-1H-indole-3-carbonyl)- L-valinate 7	7044-(9-2018)
	(P)) 5-Fluoro-ADB, or methyl 2-(1-(5-fluoropentyl)-1H- indazole-3-carboxamido)-3,3-dimethylbutanoate; 70	034-(11-2018)
	(Q	5-Fluoro-MDMB-PICA, or methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate 70)41-(11-2018)
	(R)) MDMB-CHMICA, or methyl 2-(1-(cyclohexylmethyl)-1H- indole-3-carboxamido)-3,3-dimethylbutanoate; 70	042-(11-2018)

	arboxamido)-3-methylbutanoate;	7021-(11-2018)
	MDMB-FUBINACA, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-arboxamido)-3,3-dimethylbutanoate;	7020-(11-2018)
	AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-ndazole-3-caroboxamide;	7023-(7-2019)
	AB-CHMINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-cyclohexylmethyl)-1H-indazole-3-carboxamide;	7031-(7-2019)
	MAB-CHMINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-(cyclohexylmethyl)-1H-indazole-3-carboxamide;-	
	AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-uorobenzyl)-1H-indazole-3-carboxamide;	(9-2018)
	DB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-H-indazole-3-carboxamide;	(9-2018)
	F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-H-indazole-3-carboxamide	7083-(6-2020)
(AA)	ADB-FUBINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4 fluorobenzyl)-1H-indazole-3-carboxamide	
(BB)	4-Fluoro-MDMB-BUTINACA, or methyl(S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;	- 7043-(4-2021)
(CC)	5F-AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide	- 7025-(5-2022)
(DD)	4-CN-CUMYL-BUTINACA, or 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide	7089 –(5-2022)
(EE)	5F-CUMYL-P7AICA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide	- 7085-(5-2022)
(FF)	NM2201, or Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	- 7221-(5-2022)
(GG)	5F-EDMB-PINACA, or Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate	7036
(HH)	FUB-144, or (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone;	7014
(II)	FUB-AKB48, or N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3 carboxamide;	
(JJ)	MDMB-4en-PINACA, or Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate;	
(KK)	CH-PIATA, or N-cyclohexyl-2-(1-pentylindol-3-yl)acetamide.	

- (6) A synthetic substance, derivative, or its isomers with:
 - (i) Similar chemical structure to any substance described in subdivisions (a)(1)(a)(5) of this section; or ------**
 - (ii) Similar pharmacological effects to any substance described in subdivisions (a)(1)-(a)(5) of this section. -----**
- (b) However, except as provided under subsection (c) of this section, the Secretary shall not delete a controlled substance listed in this section from Schedule VI.
- (c) A prescription drug approved by the United States Food and Drug Administration under 21 U.S.C. § 355 is excluded from Schedule VI unless the secretary objects under § 5-64-201.
 - *-Scheduled before April, 1979.
 - **-Schedule VI is revised to conform to Act 329 of 2013.
 - *** Schedule VI is revised further to conform to Act 629 of 2023. Each substance added to the Controlled Substances List pursuant to Act 629 of 2023 shall have the following effective dates:
 - (a) For persons who are under twenty-one (21) years of age, the effective date shall be the effective date of Act 629 of 2023; and,
 - (b) For persons who are twenty-one (21) years of age or older, the effective date shall be August 1, 2023.
 - **** Pursuant to ongoing litigation, and a preliminary injunction against enforcing Act 629 of 2023, the changes made to the List of Controlled Substances pursuant to Act 629 of 2023 are not enforceable until a final order issued in the matter, Bio Gen, LLC, et al. v. Sarah Huckabee Sanders, et al., Case No. 4:23-CV-00718-BRW, Central Division, Eastern District of Arkansas, United States District Court.